The effect of MDMA on anterior pituitary hormones: a secondary analysis of a randomized placebo-controlled trial

MDMA (3,4-methylenedioxymethamphetamine) is a psychoactive compound studied both recreationally and as a potential treatment for post-traumatic stress disorder. Prior animal and human work shows a robust MDMA-induced release of oxytocin from the posterior pituitary; animal studies also report stimulatory effects on anterior pituitary axes, including increases in ACTH, cortisol, TSH, thyroxine and prolactin. Human data, however, are limited and inconsistent: cortisol rises after MDMA are well documented, but whether ACTH and other anterior pituitary hormones are directly stimulated in humans remains uncertain, and no clear human data exist for pituitary-thyroid effects. Diagnosing hypopituitarism typically relies on basal measures and dynamic provocation tests, which are resource-intensive, so a single agent able to stimulate multiple pituitary axes could have diagnostic utility. Atila and colleagues performed a secondary analysis of data from a randomized, double-blind, placebo-controlled, crossover trial to test whether a single 100 mg oral dose of MDMA acutely stimulates anterior pituitary hormones in healthy adults. They hypothesised that, in addition to oxytocin, MDMA would increase secretion across multiple anterior pituitary axes and explored correlations between hormonal changes and cardiovascular and subjective psychoactive effects.

This secondary analysis used data from a double-blind, placebo-controlled, crossover trial in 15 healthy adults conducted between February 2021 and April 2022. Each participant attended two 7-hour experimental visits, receiving 100 mg oral MDMA in one session and placebo in the other, with a washout interval of at least 14 days and randomised order. Visits were standardised: participants fasted overnight, abstained from alcohol and other substances prior to each session, underwent urine drug screening, and female participants were scheduled during the follicular phase. An intravenous catheter was placed for blood sampling and physiological measures (blood pressure, heart rate, tympanic temperature) were recorded repeatedly from before dosing to beyond 120 minutes. Blood for this analysis was drawn at baseline (pre-dose) and at 120 minutes post-dose, a timepoint chosen because prior work shows peak cortisol and prolactin responses around 120 minutes and coincides with peak monoaminergic effects of MDMA. EDTA plasma was assayed for ACTH using chemiluminescent immunoassay (CLIA). Serum assays used electrochemoluminescent immunoassay (ECLIA) for TSH, free thyroxine (fT4), cortisol, LH, testosterone, estradiol, prolactin and growth hormone. Copeptin was measured with TRACE methodology and oxytocin by ELISA; follicle-stimulating hormone (FSH) was not assessed. Samples were processed promptly and stored at −80°C until batch analysis. The primary endpoints were within-subject changes in hormone levels from baseline to 120 minutes after MDMA versus placebo. Change scores and percentage changes were calculated, and paired Wilcoxon tests compared MDMA versus placebo conditions. Associations between hormonal changes and cardiovascular measures or subjective psychoactive effect (VAS for 'any drug effect') were assessed with Spearman correlations. All statistical tests were two-sided with p<0.05 as the threshold for significance; analyses were performed in R (version 4.4.2).

Fifteen healthy adults were analysed (median age 35 years [IQR 26–48]; 53% female). The principal finding was a robust activation of the hypothalamic–pituitary–adrenal (HPA) axis after MDMA: median plasma ACTH rose from 12 ng/L [11, 15] at baseline to 38 ng/L [25, 59] at 120 minutes, with the change significant (p<0.001). This ACTH increase was accompanied by a significant cortisol rise from 347 nmol/L [252, 409] to 566 nmol/L [457, 701] (p=0.006). Under placebo, ACTH showed no significant change and cortisol demonstrated a physiological decrease. Prolactin increased modestly from 12 µg/L [7, 16] to 14 µg/L [10, 22] at 120 minutes; the absolute change was 4 µg/L [−1, 12] and did not reach conventional statistical significance (p=0.062), though percentage change distributions were reported. No MDMA-induced effects were observed for the somatotropic axis (growth hormone), the pituitary–gonadal axis (LH, testosterone, estradiol) or the pituitary–thyroid axis (TSH, fT4). Oxytocin, a posterior pituitary hormone, increased markedly from 75 pg/mL [55, 94] at baseline to 504 pg/mL [192, 589] at 120 minutes (absolute change 433 pg/mL [99, 518], p<0.001), whereas copeptin did not change. Correlation analyses showed that increases in ACTH correlated with rises in systolic blood pressure (r=0.61, p<0.001), diastolic blood pressure (r=0.50, p=0.005) and heart rate (r=0.50, p=0.006), but not with temperature. Cortisol changes showed similar correlations with systolic blood pressure (r=0.62, p<0.001), diastolic blood pressure (r=0.43, p=0.019) and heart rate (r=0.39, p=0.032). Both ACTH and cortisol increases correlated with the subjective VAS 'any drug effect' (r=0.57 and r=0.66 respectively, p<0.001). Safety data indicated greater cardiovascular stimulation after MDMA than placebo (maximum systolic blood pressure 146 vs 129 mmHg; diastolic 84 vs 78 mmHg; heart rate 92 vs 78 bpm) and higher rates of transient adverse symptoms at 360 minutes (for example, fatigue 53%, lack of appetite 67%, lack of concentration 53%, dry mouth 53%) and at 3-day follow-up (headache 33%, fatigue 40%, dullness 33%, lack of energy 13%).

Atila and colleagues interpret their findings as evidence that MDMA robustly stimulates the HPA axis in humans, producing increases in ACTH that appear to drive the observed cortisol rise. They place this result within prior mechanistic literature that implicates serotonergic activation—particularly via increased extracellular serotonin—as the primary mediator of MDMA-induced HPA activation, with supporting pharmacological data showing modulation by serotonergic agents. The modest increase in prolactin is considered consistent with serotonergic stimulation of lactotrophs, although the effect was smaller and did not reach statistical significance in this sample. The investigators note that HPA and prolactin activation correlated with cardiovascular measures and subjective psychoactive effects, but they caution that the HPA response is unlikely to be the primary driver of MDMA's cardiovascular stimulation. Instead, noradrenergic mechanisms and direct sympathetic activation are emphasised as key contributors, consistent with prior pharmacological blockade studies. In contrast to rodent literature, no activation of the pituitary–thyroid axis was detected, and no effects on growth hormone or gonadotropins were observed; the authors suggest species differences and complex multi-receptor regulation as possible explanations. Potential clinical implications are discussed: MDMA's concurrent stimulation of oxytocin (posterior pituitary) and the HPA axis raises the possibility of using MDMA as a provocation agent for assessing multiple pituitary axes, particularly given limitations of current tests for adrenal insufficiency and Cushing's disease. The authors are cautious, however, and state that further validation in larger and clinical populations is required before any diagnostic application could be considered. Limitations highlighted by the authors include measurement at only two timepoints (baseline and 120 minutes), which may miss other hormonal dynamics; use of a single relatively high MDMA dose rather than dose–response data; and a small sample size (n=15), which may constrain generalisability and power to detect modest effects. Strengths include the crossover, double-blind design and the standardised, controlled experimental conditions that reduced potential confounding. The authors conclude that MDMA robustly stimulates the HPA axis and oxytocin release, with a moderate effect on prolactin, but that further research is needed to validate clinical utility.